Medivir announces the design of its upcoming MIV-818 combination study
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced the details of its upcoming phase 1/2a combination study with the company's leading candidate drug, MIV-818, against liver cancer. The unique mechanism of action of MIV-818 makes it attractive to be combined with a multitude of other targeted and non-targeted drugs for the treatment of hepatocellular carcinoma. In the upcoming combination study, MIV-818 will be administered in two combinations, either with lenvatinib, a tyrosine kinase inhibitor or pembrolizumab, an anti-PD-1 check-point inhibitor. The planned trial